Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arash Arya is active.

Publication


Featured researches published by Arash Arya.


Circulation-arrhythmia and Electrophysiology | 2014

Tailored Atrial Substrate Modification Based On Low-Voltage Areas in Catheter Ablation of Atrial Fibrillation

Sascha Rolf; Simon Kircher; Arash Arya; Charlotte Eitel; Philipp Sommer; Sergio Richter; Thomas Gaspar; Andreas Bollmann; David Altmann; Carlos Piedra; Gerhard Hindricks; Christopher Piorkowski

Background—Reduced electrogram amplitude has been shown to correlate with diseased myocardium. We describe a novel individualized approach for catheter ablation of atrial fibrillation (AF) based on low-voltage areas (LVAs) in the left atrium (LA). We sought to assess (1) the incidence of LVAs in patients undergoing AF catheter ablation, (2) the distribution of LVAs within the LA, and (3) the effect of an individualized ablation strategy on long-term rhythm outcomes. Methods and Results—In 178 patients with paroxysmal or persistent AF, LA voltage maps were created during sinus rhythm after circumferential pulmonary vein isolation. Subsequent substrate modification was confined to the presence of LVA (<0.5 mV) and inducible regular atrial tachycardias. LVAs were identified in 35% and 10% of patients with persistent and paroxysmal AF, respectively. The LA roof and the anterior, septal, and posterior wall LA were most often affected. The 12-month atrial tachycardias/AF-free survival was 62% for patients without LVAs and 70% for patients with LVAs and tailored substrate modification (P=0.3). Success rate in a comparison group of 26 LVA patients without further substrate modification was 27%. Conclusions—LVAs can be found at preferred sites in 10% of patients with paroxysmal AF and in 35% of patients with persistent AF. This is the first clinical report describing a consistent voltage-based approach for substrate modification in addition to circumferential pulmonary vein isolation irrespective of AF type. Application of this limited individualized approach may have the potential to compensate for the impaired 12-month outcome of patients with endocardial structural defects.


Circulation | 2014

Outcomes in Catheter Ablation of Ventricular Tachycardia in Dilated Nonischemic Cardiomyopathy Compared With Ischemic Cardiomyopathy Results From the Prospective Heart Centre of Leipzig VT (HELP-VT) Study

Borislav Dinov; Lukas Fiedler; Robert Schönbauer; Andreas Bollmann; Sascha Rolf; Christopher Piorkowski; Gerhard Hindricks; Arash Arya

Background— Data on the outcomes of ventricular tachycardia (VT) ablation in nonischemic dilated cardiomyopathy (NIDCM) are insufficient. The Heart Center of Leipzig VT (HELP-VT) study was conducted prospectively to compare outcomes after radiofrequency catheter ablation of VT in patients with NIDCM compared with ischemic cardiomyopathy (ICM). Methods and Results— Two hundred twenty-seven patients, 63 with NIDCM and 164 with ICM, presenting with sustained VT were ablated with radiofrequency catheter ablation. Noninducibility of any clinical and nonclinical VT was achieved in 66.7% of NIDCM and in 77.4% of ICM patients. Ablation of the clinical VT only was achieved in 18.3% of ICM and in 22.2% of NIDCM patients. There was no statistically significant difference in short-term outcomes between the 2 groups. At the 1-year follow-up, VT-free survival in NIDCM was 40.5% compared with 57% in ICM. In univariate analysis, the hazard ratio for VT recurrence was significantly higher for NIDCM (1.62; 95% confidence interval, 1.12– 2.34; P=0.01). In both the ICM and NIDCM subgroups, procedure failure and incomplete procedural success were independent predictors of VT recurrence. Conclusions— Although the short-term success rates after VT ablation in NIDCM and ICM patients were similar, the long-term outcomes in NIDCM patients were significantly worse. Complete VT noninducibility at the end of the ablation is associated with beneficial long-term outcome in NIDCM. Pursuing compete elimination of all inducible VTs is desirable and may improve the long-term success in NIDCM.


The American Journal of Gastroenterology | 2010

Thermal Esophageal Lesions After Radiofrequency Catheter Ablation of Left Atrial Arrhythmias

Ulrich Halm; Thomas Gaspar; Markus Zachäus; Stephan Sack; Arash Arya; Christopher Piorkowski; Ingrid Knigge; Gerhard Hindricks; Daniela Husser

OBJECTIVES:Radiofrequency catheter ablation in patients with left atrial arrhythmias may cause esophageal damage because of the close proximity between the posterior wall of the left atrium and the esophagus. The aim of this prospective study was to determine the incidence, endoscopic characterization, and endoluminal temperature dependency of esophageal thermal lesions after catheter ablation.METHODS:In all, 185 consecutive patients with symptomatic atrial fibrillation or left atrial macro-re-entrant tachycardia who underwent left atrial radiofrequency catheter ablation were scheduled for upper gastrointestinal endoscopy. During the ablation procedure, a non-fluoroscopic three-dimensional system for catheter orientation, computed tomography (CT) image integration, and activation mapping was used. The esophagus was intubated with a temperature probe for visualization within the three-dimensional image and for real-time intraluminal temperature monitoring.RESULTS:A total of 27 (14.6%) asymptomatic ulcer-like or hemorrhagic esophageal thermal lesions with a diameter of 2–16 mm were observed. Esophageal lesions did not occur below an intraluminal esophageal temperature of 41 °C. The maximal temperature in the esophagus was significantly higher in patients with thermal lesions than in patients without lesions (42.6±1.7 °C vs. 41.4±1.7 °C, P=0.003). For every 1 °C increase in endoluminal temperature, the odds of an esophageal lesion increased by a factor of 1.36 (95% confidence interval (CI) 1.07–1.74, P=0.012). No progression of the lesions was observed during follow-up endoscopies.CONCLUSIONS:Localized esophageal ulcer-like lesion is a frequent event after left atrial catheter ablation and can be found in patients whose intraluminal temperature has reached at least 41 °C.


International Journal of Cardiology | 2010

Influence of the duration of Holter monitoring on the detection of arrhythmia recurrences after catheter ablation of atrial fibrillation: Implications for patient follow-up

Nikolaos Dagres; Hans Kottkamp; Christopher Piorkowski; Sebastian Weis; Arash Arya; Philipp Sommer; Kerstin Bode; Jin-Hong Gerds-Li; Dimitrios Th. Kremastinos; Gerhard Hindricks

We investigated the influence of Holter duration on the detection of recurrences after ablation for atrial fibrillation (AF). Two-hundred-and-fifteen patients underwent a 7-day Holter ECG at 6 months after catheter ablation. We analyzed the number of patients who had a recurrence within the first 24, 48, 72 h etc. up to the total of 7 days. During the complete 7-day recording, 30% had a recurrence. All Holter durations ≤5 days would have detected significantly less patients with recurrence than the complete 7-day recording. A 24-hour Holter would have detected 59%, a 48-hour Holter 67% and a 72-hour Holter 80% of patients with recurrences, whereas a 4-day recording would have detected 91% of the recurrences that were detected with the complete 7-day recording. In conclusion, a Holter duration of less than 4 days misses a great portion of recurrences, whereas a 4-day recording might offer a reasonable compromise.


Circulation-arrhythmia and Electrophysiology | 2011

Steerable Versus Nonsteerable Sheath Technology in Atrial Fibrillation Ablation A Prospective, Randomized Study

Christopher Piorkowski; Charlotte Eitel; Sascha Rolf; Kerstin Bode; Philipp Sommer; Thomas Gaspar; Simon Kircher; Ulrike Wetzel; Abdul Shokor Parwani; Leif-Hendrik Boldt; Meinhard Mende; Andreas Bollmann; Daniela Husser; Nikolaos Dagres; Masahiro Esato; Arash Arya; Wilhelm Haverkamp; Gerhard Hindricks

Background— Steerable sheath technology is designed to facilitate catheter access, stability, and tissue contact in target sites of atrial fibrillation (AF) catheter ablation. We hypothesized that rhythm control after interventional AF treatment is more successful using a steerable as compared with a nonsteerable sheath access. Methods and Results— One hundred thirty patients with paroxysmal or persistent drug-refractory AF undergoing their first ablation procedure were prospectively included in a randomized fashion in 2 centers. Ablation was performed by 10 operators with different levels of clinical experience. Treatment outcome was measured with serial 7-day Holter ECGs and additional symptom-based arrhythmia documentation. Single procedure success (freedom from AF and/or atrial macroreentrant tachycardia) was significantly higher in patients ablated with a steerable sheath (78% versus 55% after 3 months, P=0.005; 76% versus 53% after 6 months, P=0.008). Rate of pulmonary vein isolation, procedure duration, and radiofrequency application time did not differ significantly, whereas fluoroscopy time was lower in the steerable sheath group (33±14 minutes versus 45±17 minutes, P<0.001). Complication rates showed no significant difference (3.2% versus 5%, P=0.608). On multivariable analysis, steerable sheath usage remained the only powerful predictor for rhythm outcome after 6 months of follow-up (hazard ratio, 2.837 [1.197 to 6.723]). Conclusions— AF catheter ablation using a manually controlled, steerable sheath for catheter navigation resulted in a significantly higher clinical success rate, with comparable complication rates and with a reduction in periprocedural fluoroscopy time. Clinical Trial Registration— URL: http://clinicaltrials.gov. Unique identifier: NCT00469638.


Circulation-arrhythmia and Electrophysiology | 2014

Comparison of CHADS2, R2CHADS2 and CHA2DS2-VASc Scores for the Prediction of Rhythm Outcomes after Catheter Ablation of Atrial Fibrillation: The Leipzig Heart Center AF Ablation Registry

Jelena Kornej; Gerhard Hindricks; Jedrzej Kosiuk; Arash Arya; Philipp Sommer; Daniela Husser; Sascha Rolf; Sergio Richter; Yan Huo; Christopher Piorkowski; Andreas Bollmann

Background—Recurrences of atrial fibrillation (AF) occur in up to 30% within 1 year after catheter ablation. This study evaluated the value of CHADS2, R2CHADS2, and CHA2DS2-VASc scores for the prediction of rhythm outcomes after AF catheter ablation. Methods and Results—Using the Leipzig Heart Center AF Ablation Registry, we documented rhythm outcomes within the first 12 months in 2069 patients (67% men; 60±10 years; 35% persistent AF) undergoing AF catheter ablation. AF recurrences were defined as any atrial arrhythmia occurring within the first week (early recurrences, ERAF) and between 3 and 12 months (late recurrences, LRAF) after ablation. ERAF and LRAF occurred in 36% and 33%, respectively. On multivariable analysis, R2CHADS2 (odds ratio [OR], 1.11; 95% confidence interval [CI], 1.02–1.21; P=0.016) and CHA2DS2-VASc (OR, 1.09; 95% CI, 1.017–1.17; P=0.015) scores as well as persistent AF and left atrial diameter were significant predictors for ERAF. Similarly, the same clinical variables remained significant predictors for LRAF even after adjustment for ERAF, which was the strongest predictor for LRAF (HR, 3.12; 95% CI, 2.62–3.71; P<0.001). However, using receiver operating characteristic curve analyses, both scores demonstrated relatively low predictive value for ERAF (area under the curve [AUC], 0.536 [0.510–0.563]; P=0.007; and AUC, 0.547 [0.521–0.573]; P<0.001 for R2CHADS2 and CHA2DS2-VASc, respectively) and LRAF (AUC, 0.548 [0.518–0.578]; P=0.002; and AUC, 0.550 [0.520–0.580]; P=0.001). Conclusions—R2CHADS2 and CHA2DS2-VASc were associated with rhythm outcomes after catheter ablation. However, AF type, left atrial diameter, and especially ERAF are also significant predictors for LRAF that should be included into new clinical scores for the prediction of rhythm outcomes after catheter ablation.


Circulation-arrhythmia and Electrophysiology | 2015

Common Genetic Variants and Response to Atrial Fibrillation Ablation

M. Benjamin Shoemaker; Andreas Bollmann; Steven A. Lubitz; Laura Ueberham; Harsimran Saini; Jay A. Montgomery; Todd L. Edwards; Zachary Yoneda; Moritz F. Sinner; Arash Arya; Philipp Sommer; Jessica T. Delaney; Sandeep K. Goyal; Pablo Saavedra; Arvindh Kanagasundram; S. Patrick Whalen; Dan M. Roden; Gerhard Hindricks; Christopher R. Ellis; Patrick T. Ellinor; Dawood Darbar; Daniela Husser

Background—Common single nucleotide polymorphisms (SNPs) at chromosomes 4q25 (rs2200733, rs10033464 near PITX2), 1q21 (rs13376333 in KCNN3), and 16q22 (rs7193343 in ZFHX3) have consistently been associated with the risk of atrial fibrillation (AF). Single-center studies have shown that 4q25 risk alleles predict recurrence of AF after catheter ablation of AF. Here, we performed a meta-analysis to test the hypothesis that these 4 AF susceptibility SNPs modulate response to AF ablation. Methods and Results—Patients underwent de novo AF ablation between 2008 and 2012 at Vanderbilt University, the Heart Center Leipzig, and Massachusetts General Hospital. The primary outcome was 12-month recurrence, defined as an episode of AF, atrial flutter, or atrial tachycardia lasting >30 seconds after a 3-month blanking period. Multivariable analysis of the individual cohorts using a Cox proportional hazards model was performed. Summary statistics from the 3 centers were analyzed using fixed effects meta-analysis. A total of 991 patients were included (Vanderbilt University, 245; Heart Center Leipzig, 659; and Massachusetts General Hospital, 87). The overall single procedure 12-month recurrence rate was 42%. The overall risk allele frequency for these SNPs ranged from 12% to 35%. Using a dominant genetic model, the 4q25 SNP, rs2200733, predicted a 1.4-fold increased risk of recurrence (adjusted hazard ratio,1.3 [95% confidence intervals, 1.1–1.6]; P=0.011). The remaining SNPs, rs10033464 (4q25), rs13376333 (1q21), and rs7193343 (16q22) were not significantly associated with recurrence. Conclusions—Among the 3 genetic loci most strongly associated with AF, the chromosome 4q25 SNP rs2200733 is significantly associated with recurrence of atrial arrhythmias after catheter ablation for AF.


Europace | 2011

Catheter ablation of atrial fibrillation using remote magnetic catheter navigation: a case–control study

Arash Arya; Ruzbeh Zaker-Shahrak; Phillip Sommer; Andreas Bollmann; Ulrike Wetzel; Thomas Gaspar; Sergio Richter; Daniela Husser; Christopher Piorkowski; Gerhard Hindricks

AIMS To compare the acute and the 6 month outcome of catheter ablation of atrial fibrillation (AF) using irrigated tip magnetic catheter and remote magnetic cathter navigation (RMN) with manual catheter navigation (MCN) in patients with paroxysmal and persistent AF. METHODS AND RESULTS In this retrospective analysis 356 patients (235 male, mean age: 57.9 ± 10.9 years) with AF (70.5%, paroxysmal) who underwent catheter ablation between August 2007 and May 2008 using either RMN (n = 70, 46 male, mean age: 57.9 ± 10.1 years, 50% paroxysmal) or MCN (n = 286, 189 male, mean age: 58.0 ± 13.9 years, 75.5% paroxysmal) were included. All patients completed an intensive follow-up strategy. Complete pulmonary vein isolation was achieved in 87.6 and 99.6% of patients in RMN and MCN groups, respectively (P < 0.05). The procedure, fluoroscopy, and radiofrequency application times were 223 ± 44 vs. 166 ± 52 min (P < 0.0001), 13.7 ± 7.8 vs. 34.5 ± 15.1 min (P < 0.0001), and 75.4 ± 20.9 vs. 53.2 ± 21.4 min (P < 0.0001) in RMN and MCN groups, respectively. Seven (10.0%) and 28 (9.8%) patients in RMN and MCN groups received antiarrhythmic medications during the follow-up (P = 0.96). All the patients completed the 6 month follow-up. Freedom from AF at 6 months was achieved in 57.8 and 66.4% of the patients in RMN and MCN groups, respectively (P = 0.196). In patients without previous AF catheter ablation procedure the freedom from AF at 6 months were 68.2 and 60.5% in the MCN and RMN groups, respectively (P = 0.36). CONCLUSION Catheter ablation using irrigated tip magnetic catheter and RMN is an effective and safe method for catheter ablation of AF. Compared to manual catheter navigation, the procedure and radiofrequency application times were longer and fluoroscopy time was shorter in the RMN group compared with the MCN group.


Journal of the American College of Cardiology | 2015

Predictive Value of Programmed Ventricular Stimulation After Catheter Ablation of Post-Infarction Ventricular Tachycardia

Miki Yokokawa; Hyungjin Myra Kim; Kazim Baser; William G. Stevenson; Koichi Nagashima; Paolo Della Bella; Pasquale Vergara; Gerhard Hindricks; Arash Arya; Katja Zeppenfeld; Marta De Riva Silva; Emile G. Daoud; Sunil Kumar; Karl-Heinz Kuck; Ronald Tilz; Shibu Mathew; Hamid Ghanbari; Rakesh Latchamsetty; Fred Morady; Frank Bogun

BACKGROUND A recent meta-analysis demonstrated a survival benefit in post-infarction patients whose ventricular tachycardia (VT) was rendered noninducible by catheter ablation. Furthermore, patients with noninducible VT had a lower VT recurrence rate than did patients whose VT remained inducible after ablation. OBJECTIVES The purpose of this multicenter cohort study was to assess whether noninducibility after VT ablation is independently associated with improved survival. METHODS Data from 1,064 patients who underwent VT ablation for post-infarction VT at seven international centers were analyzed. The ablation procedure was considered successful if no VT was inducible at the end of the procedure and unsuccessful if VT remained inducible or if programmed stimulation was not performed at the end of the ablation. RESULTS Median follow-up time was 633 days. Noninducibility was independently associated with lower mortality (adjusted hazard ratio: 0.65; 95% confidence interval: 0.53 to 0.79; p<0.001). Atrial fibrillation, diabetes, and age were other independent predictors of higher mortality. Ablation of only the clinical VT in patients who also had inducible, nonclinical VTs was not associated with improved survival. CONCLUSIONS Noninducibility after VT ablation in patients with post-infarction VT is independently associated with lower mortality during long-term follow-up.


Europace | 2013

Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation

Charlotte Eitel; Julia Koch; Philipp Sommer; Silke John; Simon Kircher; Andreas Bollmann; Arash Arya; Christopher Piorkowski; Gerhard Hindricks

AIMS Experiences with novel oral anticoagulants (NOACs) early after atrial fibrillation (AF) catheter ablation are limited and show controversial results. We aimed to assess the longer-term safety, efficacy, and acceptance of NOACs in a large real-world cohort of patients presenting for AF catheter ablation. METHODS AND RESULTS From July 2010 until June 2012, 259 patients undergoing AF catheter ablation were prospectively included. Novel oral anticoagulants were given for at least 3 months post-ablation. Clinical outcome (stroke, thromboembolic events, major bleeding), adverse effects, and drug adherence were assessed at discharge and follow-up. On admission patients were presented with a variety of anticoagulants including 54 patients (21%) already on NOACs prior ablation. After ablation 38% of patients received dabigatran 110 mg, 56% 150 mg, and 6% received rivaroxaban 20 mg. There were four periprocedural thromboembolic and major bleeding complications (1.5%), all in patients without NOACs prior ablation (two on warfarin and two on heparin). During long-term follow-up [311 (199; 418) days] no stroke, systemic embolism, or major haemorrhage could be observed. Uneventful electrical cardioversions and reablation procedures were performed in 27 and 12 patients on dabigatran, respectively. Novel oral anticoagulants were prematurely stopped or switched to another anticoagulant due to side effects or at the preference of the treating general practitioner in 9 and 10 patients, respectively. CONCLUSION In this prospective observational study, anticoagulation with NOACs following AF catheter ablation was safe and effective at long-term follow-up. Fast onset of action makes NOACs especially attractive in patients without effective anticoagulation on admission and in patients following periprocedural complications.

Collaboration


Dive into the Arash Arya's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge